A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186—Trials in progress

MLA

Efrat Dotan, et al. “A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment-Naïve Metastatic Pancreatic Cancer (GIANT): ECOG-ACRIN EA2186—Trials in Progress.” Journal of Clinical Oncology, vol. 40, June 2022, p. TPS4185. EBSCOhost, https://doi.org/10.1200/jco.2022.40.16_suppl.tps4185.

APA

Efrat Dotan, Paul J. Catalano, Leon Lenchik, Robert Boutin, Xin Yao, Shaalan Shaalan Beg, Namrata Vijayvergia, Constantine Gatsonis, David Bing Zhen, Daneng Li, Lynne I. Wagner, Melissa A. Simon, Terence Z. Wong, & Peter J. O’Dwyer. (2022). A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186—Trials in progress. Journal of Clinical Oncology, 40, TPS4185. https://doi.org/10.1200/jco.2022.40.16_suppl.tps4185

Chicago

Efrat Dotan, Paul J. Catalano, Leon Lenchik, Robert Boutin, Xin Yao, Shaalan Shaalan Beg, Namrata Vijayvergia, et al. 2022. “A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment-Naïve Metastatic Pancreatic Cancer (GIANT): ECOG-ACRIN EA2186—Trials in Progress.” Journal of Clinical Oncology 40 (June): TPS4185. doi:10.1200/jco.2022.40.16_suppl.tps4185.